Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
10 million shares today at 1:24 ET. I do not see any news. Has anybody communicated with IR? Is VitaStem still the only product for sale? Is Amazon the only point of sale? What are the other websites that sell VitaStem? Are hospitals purchasing the larger size VitaStem bottle announced three months ago? Which product is next to launch? Any insights or speculations are welcome.
On the Canadian exchange this stock trades as PILL I think. Is there another investor board where the company is discussed in either English or French? A tablet is an important development. Why is nobody interested? Is there competition that I am not aware about?
55 million shares and no particular news. Maybe the cream patent getting issued and being so broad is getting acknowledged. The issue date was 03/31. No PR was given.
Today being 04/20 could also be a factor in the 115% gain.
One thing about SGMD is vertical integration. They can grow it themselves and then sell it retail.
There is also a Florida facility for CBD tablets. No THC in Florida I believe. Manufacturing a pharmaceutical might be considered to be an essential activity in a Covid -19 restricted economy. Maintaining social distancing might be a doable thing to accomplish in a manufacturing setting.
How many employees does Canntab currently have? Are they hiring a sales force?
What sort of intellectual property does CTABF have that would stop a competitor from copying their cannabinoid tablets? The patents I understand are pending and not yet granted.
Precise medical dosing has to be a widely sought after product that health care providers could confidently recommend or prescribe? OWCP has a tablet. Who else is tablet competition? GWPC might be a buyer for a medical grade tablet.
What is the current status of the 5 or so patents that are pending? Is the company viable if the patents are denied?
What is the monthly cash burn for PTN?
Does SGMD own all of BudCars or only 40% of BudCars? If there is a buyout agreement what is the price for the other 60% of BudCars?
Is it possible to track VitaStem sales on Amazon? If anything that Dr Otiko has said he is going to do really does happen, then the stock price would have to go up, at least for short time.
The current stock price of 0.0011 reflects that there is very little faith that there is anything honest or productive happening here at VDRM. That could indeed be the truth for all I know.
The storyline of the topical medications has a certain appeal that serves as bait perhaps to catch small fish like me.
Did Dr. Otiko close down his Podiatry practice? Is it a Covid-19 temporary closure? Does he see his emergency patients? Is he in good standing with the California Podiatry Board?
What then is the use of an attorney letter? What does the letter say? I assume it needs to be an attorney to testify or report that laws are being obeyed or complied with.
Thanks IG. This is all interesting news. He says it is for personal reasons. If it were due to SEC legal reasons that could still be considered a personal reason. Perhaps it is the Jeffrey Friedland affair that is lingering or something else like the DGF convertible note deal that was structured with a prior knowledge of a possible sexual crimes triggering event.
OWCP has been a freak show to watch. It does seem to me as though the OWCP skin diseases patent would fit nicely inside the MNLO portfolio of IP. Now I am watching MNLO. $1 might be a good low entry point.
What do people think is the value of the OWCP Skin Diseases patent issued March 31 without any PR whatsoever? Thanks in advance for any insights.
Why would the previous management want to keep any good news like a patent approval or grant from getting PRed? These people have a lot of shares of OWCP that they own themselves. Why would they not want to see the price of their own shares go up?
Most companies it would seem to me would announce positive news.
Thanks for any insight here.
The next positive news was to my understanding going to be an “attorney letter” to the OTC or the SEC and then we were hoping to attain an OTC website status level of “current.” When that happens, then we were looking to see the yield sign removed.
What sort of timeframe do we expect all this to entail? What would the attorney letter swear to specifically to be true? Would an attorney refuse to write a letter for Dr. Otiko?
Is VDRM still be at risk at this time of getting shut down by the SEC for noncompliance issues or fraud. Another status change is perhaps being moved to a grey market exchange?
Thanks in advance for any insight here.
If the publicly stated intentions for the new products are true I have an intuition that there is indeed a market for it. A market that is bigger than the market for Vitastem alone. The new ones are Elixer, Prolayed, and the topical pain medication. Are there any others?
What and when might the next catalyst event occur for CTABF. Would it be manufacturing news? or distribution news? Or sales news? Or patent approval? Or pharmacokinetic study results? Anybody have any intuition or knowledge in this area of medical cannabis?
With OWCP suspending it’s tablet program that leaves CTABF in the medical dosing arena much or any known competition. CVSI might have an interest in this area of medical cannabis. What other competitors want a tablet? GW Pharmaceuticals is another obvious suspect.
Thanks in advance for any helpful insight here.
OWCP market cap is below $2 million. The recently awarded patent must be worth more than that by many multiples. If the patent is worth $50 million that would mean a share price of 25 cents. If the patent is worth $100 million then the share price would be 50 cents. There is also other relevant IP such as the Multiple Myeloma treatment patent application. There is also the sublingual tablet.
IG thinks the patent is worthless. What do other people think that the patent is worth? GW Pharm could take ownership of the patent and then complete the clinical trials.
If OWCP did receive a Wells Notice would that be considered to be a material event and therefore would be requiring a shareholder notification from the company?
Is it notably unusual that we have not yet heard any substantial explanation about the change in management?
Could a Wells Notice be a reason for the recent change in management?
How much of a high weight anchor are the DGF (Discovery Growth Fund aka Mr. Sims) convertible notes at this time? Did the run to $0.15 allow a significant portion of that debt to be paid off? That would be nice to hear about.
Would an Investor Relations officer who actively communicates with shareholders be an intelligent use of available OWCP company resources?
When the company officially gets a patent for the psoriasis cream soon would they even bother to put out a PR?
Can men be prescribed Vyleesi on a off label basis? AMAG is not allowed by the FDA to market the drug to men, however a physician should be able to use his or her own professional judgement if it could be medically helpful in men. Does anybody know about the legality of “off label “ uses of Vyleesi for men?
Up 42% in one day. Does somebody know something?
It is amazing how 1000 shares can move the pps from .0009 to .0011 a movement of 23% in price. The cost of 1000 shares is one dollar. I think that GM would call that a paint job.
I think that we have around 700 million shares outstanding. At around .001 per share VDRM market cap is around $700,000.
What would be considered a fair value? What is the comparison to Book Value? Do fundamentals apply to a company such as VDRM? The value could be a multiple of sales revenue. With four or five products being sold through various different channels in the future what sort of revenue could we imagine for VDRM in the future?
Thanks.
Thanks Lazed. With the recent offering I think there is less than 3.5 million shares outstanding. At $1.27 NVIV market cap is around $4.2 million. The NVIV company has now $7 million in cash. The expenses are mostly paying executive salaries and bonuses.
The first spinal surgery trials showed big promise but at the very end one patient died , but the death was totally unrelated to spinal surgery. The addition of nerve growth factors and/or stem cells could increase positive patient outcomes in the future. This should be a high priority area of research.
To start to have an effective treatment for paralysis in humans , where in the past there was no treatment at all, should be worth something, but the stock market sees little or no value in the Neural spinal scaffold (NSS) it seems.
How much more money will NVIV need to spend before completion of Inspire 2.0? Do the research medical centers bill NVIV for all the surgical costs and follow up care? Is it around 24 patients total?
Thanks.
Is the market cap now lower than the cash on hand?
What percentage of the market cap are the annual executive salaries? Perhaps these benevolent people could suspend their salary for one year to help the company survive and so shareholders do not get diluted further.
With 16 medical centers now participating in the spinal injury treatment trials how long are we expecting to wait for trial results? Thanks.
Is the market cap now lower than the cash on hand?
Wow. $28.28
Bremelanotide is Vyleesi. I believe it works. The financial markets seem to believe it is not marketable or does not work.
What kind of sales would Corticotropin expect to get? What are the odds that ANIP will get final approval for Corticotropin? When are we expecting this announcement to occur? Call options with an expiration after that date might be a rewarding investment.
Thanks.
1000 traded at 0.004. Not down at all. More stable than travel stocks.
A previous post points out that cash on hand per share is at around 40 cents per share. Vyleesi is valued already at a very low level. With some marketing for the peptide this may not be a fact that bremelanatide is indeed a failure.
I wonder about the possibility of a patch.
There is also a pipeline that has some hope justified in it.
I use the bremelanotide peptide myself. It is a bit more of an effect than a placebo effect I think. I wish some of you investors would try it out for yourselves and report about your experience here on IHub.
What would be considered a “Book Value” here for PTN?
VDRM down 12% in a flash with some volume.
Is there a logical bottom to think about with a stock like SGMD or is it .0001 that we are to expect? Is there a book value? Are there any assets that have a value? This stock was once at 40 cents per share not that long ago. Today it is 0.00265.
How could things possibly go wrong to this extent in such a fairly short period of time?
Cannabis stocks are under selling duress in general, but SGMD is more detested than most it appears to me.
I suppose my question is this: Is there a fair value that could be assigned to SGMD below which an investor would intelligently consider buying stock and not be a total fool?
We are waiting for an attorney letter to lift the Yield Sign on the OTC website. What exactly does the attorney letter testify to? We are also listed a a shell risk. At what point does shell risk status get lifted?
Thanks biopicker, Nice to see some advertising. Is there also targeted advertising on TV? If Oprah were to recommend it that would be a big help. I have never seen an ad on TV. It says not for use in men. I think that is wrong except the dosing for men is different. Men are bigger and might need a higher dose. The woman’s dose would not be a danger.
The important thing to remember here is that it does work in men maybe better than in women.
GRSU is actually trading a little bit. Not much but not absolutely nothing at all. Rik’s other venture NP## is up 800 % in recent months due to overcoming an SEC existential threat. If Rik is flush again soon from NP## getting out of the woods, he might start to think again about the cannabis beverage segment again. The cost of entry into the business should not be too great. It is FDA regulation that would be the biggest issue.
Is GRSU trading on OTC or on a “grey” market?
Does anyone know with any degree of specificity what it is in concrete terms that JZZI is working on? It has to do with media and entertainment and being a disruptor. It might be some sort of streaming enterprise.
The spread in this stock is bid .2974 and ask .4046. There is no volume today on OTC. I know that lower volume leads to bigger spreads. However the large spread could also hamper volume. Market makers are given the task of adding liquidity to an equity. Does the SEC put any requirements on spread percentages presented in order to be a market maker? The price volatility is what should also determine the spread. We have little price volatility though down around 50% perhaps in a year.
The volume of trades seems subdued here on the OTC. Is the volume of trades on the Canadian Trading Board a lot higher or also quite subdued? With a tablet approach to administration of cannabinoids this company should be providing what the people and medical providers want to see happen.
CTABF and OWCP are two companies working on a tablet. Such a tablet would need to have intellectual property protection to avoid being copied. A tablet itself seems obvious. It would be something about new technology in the tablet design that could be patented it seems to me.
Has IR communicated with anyone who is on this board recently? Is it worth it to try to reach out to them for information? They cannot tell me anything that is not public knowledge due to fair disclosure laws.
I would like to know the status of the patent that is pending. I would like to know more about the Elixer CBD project. I would like to know more about our line of credit. What is the interest rate for example. We don’t hear many details about Prolayed. What sorts of sales figures can we expect for Vitastem , Prolayed and other products online and at Amazon?
There are many questions that an investor should have with VDRM because news flow from the company has been notably sparse for 18 months. We did get a blip of info 8 days ago from Dr, Otiko that he is behind the scenes and working hard for us, the shareholders. (Stock price more than doubled on that). We also see a 2020 add for Elixer mentioning Viaderma transdermal technology.
We need to know that the company is trying to stay current with the OTC reporting requirements. The Stop Sign is bad publicity. With a new line of credit this should be a priority to get done.
I think IR is allowed to say what they are doing and planning to get done if widely disseminated. In terms of complying with fair disclosure rules and any possible lawsuit it might be smartest and easiest to say nothing at all to investors.
Can sublingual pills sales and dermal cream sales commence prior to a patent for the pill or FDA approval for the cream? I do believe that we have already proven safety for the cream. Medical Cannabis Dispensaries in the USA do not need FDA approval. Canada might also be open for sales. I think the home country of Israel is also a possible market.
To get into regular pharmacies would require that the US Congress or that the DEA on it’s own would reclassify THC to a lower schedule than schedule 1 which has no medical use.
Without Where’sWeed and InfusionZ what has DVLP got going for it to be hopeful of a prosperous future for the company?
Is now a good time to launch a cannabis based beverage?
JZZ Tech is merging with LPMG. The market niche is disruption of media and entertainment markets. Can anyone paint some color about what sorts of disruptions we are or could be involved in?
Dr. Otiko stated that the proprietary dermal transport technology was “patent pending”. What is the outlook for this patent? It seems like an important question.